Literature DB >> 26422428

Quality of life and functional disability in patients with interstitial lung disease related to Systemic Sclerosis.

Federica Lumetti1, Lissette Barone, Cristina Alfieri, Mario Silva, Valter Serra, Giovanni Delsante, Nicola Sverzellati, Alarico Ariani.   

Abstract

BACKGROUND: Systemic Sclerosis (SSc) is a connective disease impairing respiratory function. SSc worsens patients' Health Assessment Questionnaire (HAQ-DI), Short Form 36 Physical and Mental Component Summary (SF36-PCS and SF36-MCS). The aim of this work is to verify whether there is correlation between quality of life and lung interstitiopathy in SSc patients.
METHODS: SF36 and HAQ-DI were given to each patient (48 in all). Lung involvement was evaluated with Baseline Dyspnea Index (BDI), spirometry and pulmonary fibrosis radiological assessment (PFRA). Correlations between SF36, HAQ-DI and lung involvement severity were investigated with Spearman's rank test. A p-value<0.05 was considered statistically significant.
RESULTS: SF36-PCS and SF36-MCS correlate with BDI (respectively rho=0.553 p=0.0001; rho=0.357 p=0.0150). The best correlating SF36 subsets are Physical Role (rho =0.566 p<0.0001) and Bodily Pain (rho=0.444 p=0.0020). BDI correlates with HAQ-DI (rho=-0.655 p<0.0001). No statistically significant correlation was found between SF36, HAQ-DI and spirometrical values nor PFRA.
CONCLUSIONS: The SSc patients enrolled have an impaired quality of life as widely demonstrated in literature. Quality of life reduction and functional ability decrease are only related to respiratory subjective impairment (assessed by BDI). Actually no correlation with objective lung damage (assessed by spirometry and PFRA) was detected.

Entities:  

Mesh:

Year:  2015        PMID: 26422428

Source DB:  PubMed          Journal:  Acta Biomed        ISSN: 0392-4203


  3 in total

1.  Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II.

Authors:  Elizabeth R Volkmann; Donald P Tashkin; Holly LeClair; Michael D Roth; Grace Kim; Jonathan Goldin; Philip J Clements; Daniel E Furst; Dinesh Khanna
Journal:  ACR Open Rheumatol       Date:  2020-05-20

2.  Factors associated with quality of life in systemic sclerosis: a cross-sectional study.

Authors:  Matylda Sierakowska; Halina Doroszkiewicz; Justyna Sierakowska; Marzena Olesińska; Agnieszka Grabowska-Jodkowska; Marek Brzosko; Piotr Leszczyński; Katarzyna Pawlak-Buś; Bogdan Batko; Piotr Wiland; Maria Majdan; Małgorzata Bykowska-Sochacka; Wojciech Romanowski; Aleksandra Zon-Giebel; Sławomir Jeka; Mwidimi Ndosi
Journal:  Qual Life Res       Date:  2019-09-03       Impact factor: 4.147

3.  Natural History of Systemic Sclerosis-Related Interstitial Lung Disease: How to Identify a Progressive Fibrosing Phenotype.

Authors:  Elizabeth R Volkmann
Journal:  J Scleroderma Relat Disord       Date:  2019-12-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.